{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:51:39Z","timestamp":1784263899675,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070152, 81770152, 81570143"],"award-info":[{"award-number":["82070152, 81770152, 81570143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>V-type immunoglobulin domain-containing suppressor of T cell activation (VISTA) is considered as an immunosuppressive factor and potential therapeutic target for anticancer therapy. However, little is known about VISTA expression and its role in immunosuppression in multiple myeloma (MM). In this study, VISTA expression and co-expression with programmed cell death receptor-1 (PD-1), T cell immunoglobulin mucin-domain-containing-3 (Tim-3), and T cell immunoglobulin and ITIM domain (TIGIT) in CD3+, CD4+, CD8+, and regulatory T (Treg) cells were analyzed in patients with MM by multi-color fluorescent flow cytometry of peripheral blood (PB) and bone marrow (BM) samples from 36 patients with MM and compared to 36 PB samples and 10 BM samples from healthy individuals (HIs), which served as controls. The results demonstrated a significant increased percentage of VISTA co-expression with PD-1, Tim-3, and TIGIT in CD3+, CD4+, CD8+, and Treg cells in PB from MM patients compared with HIs. A similar trend for VISTA+CD8+ T cells was found in BM. Moreover, a trend of a high percentage on VISTA expression and co-expression in PB rather than BM was found. Furthermore, significant positive correlations existed for VISTA expression concurrent with PD-1, Tim-3, and TIGIT in T cell subsets and clinical indicators, including Revised International Staging System (R-ISS) staging of multiple myeloma, Eastern Cooperative Oncology Group (ECOG) score, and beta-2-microglobulin (\u03b22-MG). In conclusion, higher VISTA expression concurrent with PD-1, Tim-3, and TIGIT on T cells, particularly in the PB of patients with MM, may result in T cell exhaustion and dysfunction and be closely associated with disease progression and clinical indicators. Thus, VISTA may be considered a potential target for reversing T cell exhaustion and improving T cell function in MM.<\/jats:p>","DOI":"10.3389\/fonc.2022.1014904","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T07:17:56Z","timestamp":1668064676000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuxin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liye","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/ijms22073587","article-title":"Immunological prognostic factors in multiple myeloma","volume":"22","author":"B\u0119bnowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/cancers13061285","article-title":"Multiple myeloma: Heterogeneous in every way","volume":"13","author":"Schavgoulidze","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22049","article-title":"Increased tox expression concurrent with pd-1, Tim-3, and Cd244 expression in T cells from patients with acute myeloid leukemia","volume":"102","author":"Huang","year":"2021","journal-title":"Cytom B Clin Cytom"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.763773","article-title":"Bone marrow-resident V\u03b41 T cells Co-express tigit with pd-1, Tim-3 or Cd39 in aml and myeloma","volume":"8","author":"Brauneck","year":"2021","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40364-021-00275-y","article-title":"Tox as a potential target for immunotherapy in lymphocytic malignancies","volume":"9","author":"Liang","year":"2021","journal-title":"biomark Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting pd-1\/Pd-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T Cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.14715\/cmb\/2018.64.5.19","article-title":"Analysis of peripheral blood T-cell subsets and regulatory T-cells in multiple myeloma patients","volume":"64","author":"Huang","year":"2018","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13033","article-title":"Increased exhausted Cd8(+) T cells with programmed death-1, T-cell immunoglobulin and mucin-Domain-Containing-3 phenotype in patients with multiple myeloma","volume":"14","author":"Tan","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-0267","article-title":"Pd-1 blockade reinvigorates bone marrow Cd8(+) T cells from patients with multiple myeloma in the presence of tgf\u03b2 inhibitors","volume":"26","author":"Kwon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cellimm.2018.10.003","article-title":"The challenges of checkpoint inhibition in the treatment of multiple myeloma","volume":"334","author":"Paul","year":"2018","journal-title":"Cell Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676181","article-title":"The role of V-domain ig suppressor of T cell activation (Vista) in cancer therapy: Lessons learned and the road ahead","volume":"12","author":"Hosseinkhani","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3390\/cancers13092219","article-title":"V-Domain ig suppressor of T cell activation (Vista) expression is an independent prognostic factor in multiple myeloma","volume":"13","author":"Mutsaers","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.148","article-title":"The structure, expression, and multifaceted role of immune-checkpoint protein vista as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation","volume":"15","author":"Xu","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0190-5","article-title":"A new vista on combination therapy for negative checkpoint regulator blockade","volume":"4","author":"Deng","year":"2016","journal-title":"J immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.008","article-title":"Vista: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","article-title":"Vista: An immune regulatory protein checking tumor and immune cells in cancer immunotherapy","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/itt.S260429","article-title":"Vista: A promising target for cancer immunotherapy","volume":"10","author":"Tagliamento","year":"2021","journal-title":"ImmunoTargets Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.03.006","article-title":"Expression and significance of pd-1, Tim-3 and vista on T cell of acute myeloid leukemia patients","volume":"28","author":"Ge","year":"2020","journal-title":"J Exp Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1469594","article-title":"Vista is highly expressed on mdscs and mediates an inhibition of T cell response in patients with aml","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1038\/s41598-020-71216-2","article-title":"The prognostic significance of vista and Cd33-positive myeloid cells in cutaneous melanoma and their relationship with pd-1 expression","volume":"10","author":"Choi","year":"2020","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"21504","DOI":"10.1038\/s41598-021-00835-0","article-title":"The immune checkpoint vista exhibits high expression levels in human gliomas and associates with a poor prognosis","volume":"11","author":"Ghouzlani","year":"2021","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1968-0","article-title":"Expression of vista correlated with immunosuppression and synergized with Cd8 to predict survival in human oral squamous cell carcinoma","volume":"66","author":"Wu","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02906-7","article-title":"Expression of vista on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-Muscle-Invasive bladder cancer","volume":"70","author":"Seo","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B26","article-title":"Expression and clinicopathological significance of Foxp3 and vista in cervical cancer","volume":"13","author":"Li","year":"2021","journal-title":"Am J Trans Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12885-018-4435-1","article-title":"Vista expression associated with Cd8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-2542","article-title":"Spatially resolved and quantitative analysis of Vista\/Pd-1h as a novel immunotherapy target in human non-small cell lung cancer","volume":"24","author":"Villarroel-Espindola","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02554-3","article-title":"Expression of the immune checkpoint vista in breast cancer","volume":"69","author":"Zong","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00262-019-02434-5","article-title":"Vista expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer","volume":"69","author":"Zong","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1581546","article-title":"The expression of the immune checkpoint regulator vista correlates with improved overall survival in Pt1\/2 tumor stages in esophageal adenocarcinoma","volume":"8","author":"Loeser","year":"2019","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1907059","article-title":"Vista and pd-L1 synergistically predict poor prognosis in patients with extranodal natural Killer\/T-cell lymphoma","volume":"10","author":"He","year":"2021","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by vista: A mechanism of acquired resistance to anti-Pd-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4308","article-title":"Vista is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-022-00394-0","article-title":"Igsf11 and vista: A pair of promising immune checkpoints in tumor immunotherapy","volume":"10","author":"Tang","year":"2022","journal-title":"biomark Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13545","article-title":"Increased tox expression concurrent with pd-1, Tim-3, and Cd244 in T cells from patients with non-Hodgkin lymphoma","volume":"18","author":"Huang","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbmt.2019.08.009","article-title":"T Cell transcriptional profiling and immunophenotyping uncover Lag3 as a potential significant target of immune modulation in multiple myeloma","volume":"26","author":"Lucas","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108093","article-title":"Highly proliferative and functional pd-1(+) and Tim-3(+) T cells are transiently increased in multiple myeloma following autologous hematopoietic stem cell transplantation","volume":"100","author":"Batorov","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"20846","DOI":"10.1038\/s41598-020-77941-y","article-title":"Quantitative and functional characteristics of circulating and bone marrow pd-1- and Tim-3-Positive T cells in treated multiple myeloma patients","volume":"10","author":"Batorov","year":"2020","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.11","article-title":"Targeting Pd1-Pdl1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/leu.2013.310","article-title":"Coinhibitory molecule pd-1 as a potential target for the immunotherapy of multiple myeloma","volume":"28","author":"Atanackovic","year":"2014","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-022-00267-0","article-title":"Increased tox expression associates with exhausted T cells in patients with multiple myeloma","volume":"11","author":"Zhao","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-0185-8","article-title":"Increased pd-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with aml","volume":"8","author":"Tan","year":"2020","journal-title":"biomark Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities","volume":"13","author":"Botta","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.3390\/jcm10194588","article-title":"Regulatory T-cells and multiple myeloma: Implications in tumor immune biology and treatment","volume":"10","author":"Hadjiaggelidou","year":"2021","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1832968","article-title":"Regulatory T cells and their prognostic relevance in hematologic malignancies","volume":"2017","author":"D\u2019Arena","year":"2017","journal-title":"J Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1579324","article-title":"Evaluating the role of tregs in the progression of multiple myeloma","volume":"60","author":"Lad","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9298","DOI":"10.3390\/ijms22179298","article-title":"Deregulated expression of immune checkpoints on circulating Cd4 T cells may complicate clinical outcome and response to treatment with checkpoint inhibitors in multiple myeloma patients","volume":"22","author":"Kulikowska de Na\u0142\u0119cz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1714","article-title":"Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional Cd4(+)Pd-1(+) cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740642","article-title":"Higher tox genes expression is associated with poor overall survival for patients with acute myeloid leukemia","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1014904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T07:18:00Z","timestamp":1668064680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1014904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":51,"alternative-id":["10.3389\/fonc.2022.1014904"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1014904","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"article-number":"1014904"}}